TOVX צמיחת רווח נקי למניה השנה Theriva Biologics, Inc.

Theriva Biologics, Inc. (TOVX) is pursuing the expansion of its VCN-01 oncolytic drugs to combat solid tumors. The annual earnings per share trend reflects a dynamic where 88.00 serves as the current metric. Future company revenues will be based on royalties from partners for microbiome protection technologies. Currently, the business relies on existing liquidity to cover R&D expenses.
פילוחים אנליטיים ודוחות נתונים של חברת Theriva Corp (TOVX)

Investors view Theriva Biologics, Inc. (TOVX) as a high-risk asset with M&A potential driven by the development of VCN-01. This metric measures the year-over-year dynamics of net earnings per share, allowing for the tracking of capitalization rates without reporting delays. By analyzing the final annual EPS growth figure, one can assess the impact of clinical successes on the fundamental value of this biotechnology company.